⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38800 | 1.00 | — | — | |
| Water SCHEMBL7290181 | 0.94 | — | — | |
| Water SCHEMBL7315178 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL9808559 | 0.94 | — | — | |
| SCHEMBL6651200 | 0.94 | — | — | |
| SCHEMBL2121176 | 0.94 | — | — | |
| Hydroxyamine SCHEMBL10528078 | 0.88 | — | — | |
| Boric Acid SCHEMBL28199347 | 0.86 | — | — | |
| SCHEMBL28100509 | 0.85 | — | — | |
| Bicarbonate SCHEMBL8820662 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090219-A1 | ADROPIN AS A BIOMARKER FOR CARDIOMETABOLIC DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4398892-A1 | CARDIAC ORGANOID AND ANTI-ELECTRO-MITOCHONDRIAL DESYNCHRONIZATION THERAPY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2024-07-17 | — | — | EP | claimed |
| CN-118302158-A | Cardiac organoids and anti-electro-mitochondrial dyssynchrony therapy | 耶路撒冷希伯来大学伊萨姆研发有限公司 | 2024-07-05 | — | — | CN | claimed |
| WO-2023037371-A9 | CARDIAC ORGANOID AND ANTI-ELECTRO-MITOCHONDRIAL DESYNCHRONIZATION THERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-05-16 | — | — | WO | claimed |
| US-20240115554-A1 | METHODS FOR TREATING OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY | CYTOKINETICS, INCORPORATED | 2024-04-11 | — | — | US | claimed |
| WO-2024031016-A1 | METHODS FOR TREATING OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY | CYTOKINETICS, INCORPORATED (US) | 2024-02-08 | — | — | WO | claimed |
| WO-2023037371-A1 | CARDIAC ORGANOID AND ANTI-ELECTRO-MITOCHONDRIAL DESYNCHRONIZATION THERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-16 | — | — | WO | claimed |
| US-20230054407-A1 | OPTICAL BIOPSY STAIN PANELS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-02-23 | — | — | US | claimed |
| US-11047865-B2 | Troponin and BNP based diagnosis of risk patients and cause of stroke | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2021-06-29 | — | — | US | claimed |
| US-11016102-B2 | — | — | 2021-05-25 | — | — | US | claimed |
| WO-2020236631-A1 | FLECAINIDE COMBINATION AND CONTROLLED-RELEASE FORMULATIONS FOR TREATING HEART DISEASES | ALSAR LTD PARTNERSHIP (US) | 2020-11-26 | — | — | WO | claimed |
| CN-110678195-A | ALK4 ActRIIB heteromultimer and uses thereof | 阿塞勒隆制药公司 | 2020-01-10 | — | — | CN | claimed |
| EP-3522913-A1 | ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF | Acceleron Pharma Inc. (US) | 2019-08-14 | — | — | EP | claimed |
| US-20180344666-A1 | VITAMIN K-ENRICHED LIPID EMULSION FORMULATIONS FOR THE TREATMENT OF PHARMA TOXICITY | RESQ PHARMA LLC | 2018-12-06 | — | — | US | claimed |
| WO-2018067879-A1 | ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF | ACCELERON PHARMA INC. (US) | 2018-04-12 | — | — | WO | claimed |
| EP-3160464-A1 | USE OF BUSPIRONE METABOLITES | Contera Pharma APS (DK) | 2017-05-03 | — | — | EP | claimed |
| US-20160003857-A1 | METHODS AND SYSTEMS FOR DETECTING POLYPHARMACY | BENNETT CECIL (US) | 2016-01-07 | — | — | US | claimed |
| WO-2015197079-A1 | USE OF BUSPIRONE METABOLITES | CONTERA PHARMA APS (DK) | 2015-12-30 | — | — | WO | claimed |
| US-20110123612-A1 | PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER | HANALL BIOPHARMA CO., LTD (KR) | 2011-05-26 | — | — | US | claimed |
| US-20110052683-A1 | PHARMACEUTICAL PREPARATION FOR TREATING CARDIOVASCULAR DISEASE | HANALL BIOPHARMA CO., LTD. (KR) | 2011-03-03 | — | — | US | claimed |